| For: | Oltean S. Modulators of alternative splicing as novel therapeutics in cancer. World J Clin Oncol 2015; 6(5): 92-95 [PMID: 26468443 DOI: 10.5306/wjco.v6.i5.92] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i5/92.htm |
| Number | Citing Articles |
| 1 |
Ilaria Martelli, Lucia Annamaria Cappabianca, Paola Cipriani, Antonietta Rosella Farina, Maddalena Sbaffone, Andrew Reay Mackay. Alternative Splicing in Human Viral Oncogenesis and Tumor Progression. Cancers 2026; 18(12) doi: 10.3390/cancers18122004
|
| 2 |
Atsushi Nishida, Ayaka Oda, Atsuko Takeuchi, Tomoko Lee, Hiroyuki Awano, Naohiro Hashimoto, Yasuhiro Takeshima, Masafumi Matsuo. Staurosporine allows dystrophin expression by skipping of nonsense-encoding exon. Brain and Development 2016; 38(8) doi: 10.1016/j.braindev.2016.03.003
|
| 3 |
Athina Mavrou, Sebastian Oltean. SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacological Research 2016; 107 doi: 10.1016/j.phrs.2016.03.013
|
| 4 |
Ilaria Martelli, Lucia Anna-Maria Cappabianca, Maddalena Sbaffone, Antonietta Rosella Farina, Andrew Reay Mackay. Alternative Splicing of the NF-Y Subunit, NF-YA, in Neuroblastoma Phenotype Heterogeneity. Cancers 2026; 18(11) doi: 10.3390/cancers18111839
|
| 5 |
Sreenivasan Ponnambalam, Dhananjay Jade, Michael A. Harrison, Samit Chakrabarty, Sam L. Stephen. Targeting the LOX-1 scavenger receptor for therapeutics and diagnostics. Expert Opinion on Therapeutic Targets 2026; doi: 10.1080/14728222.2026.2738346
|
| 6 |
Feng Li, Ping Yi, Jingnan Pi, Lanfang Li, Jingyi Hui, Fang Wang, Aihua Liang, Jia Yu. QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis. Oncotarget 2016; 7(22) doi: 10.18632/oncotarget.8739
|
| 7 |
Megan Stevens, Monica L. Ayine, Kim Gooding, Angela Shore, Pedro Marqueti, Sebastian Oltean, Lipi Buch. Splice Isoforms of the Apoptosis Gene BCL-X Have Opposing Effects in Diabetic Kidney Disease: Potential Treatment Target and Prognostic Value. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/2840106
|
| 8 |
Barbara Rizzacasa, Elena Morini, Sabina Pucci, Michela Murdocca, Giuseppe Novelli, Francesca Amati. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies. International Journal of Molecular Sciences 2017; 18(2) doi: 10.3390/ijms18020290
|
| 9 |
Duygu Duzgun, Sebastian Oltean. Aberrant Splicing as a Mechanism for Resistance to Cancer Therapies. Cancers 2025; 17(8) doi: 10.3390/cancers17081381
|
| 10 |
Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma. Cancer Medicine 2023; 12(4) doi: 10.1002/cam4.5174
|